Yumanity Therapeutics is a biopharmaceutical company that develops treatments for neurodegenerative diseases by discovering disease-modifying therapies. Their lead program, YTX-7739, is a small molecule being tested in clinical trials for Parkinson's disease and related disorders of a-synuclein. They also have a license and research agreement with Merck Sharp & Dohme Corp.